Cell biology: Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi

Science

Volumn 309, Issue 5744, 2005, Pages 2185-2189

  Cowen, Leah E ^a   Lindquist, Susan ^a  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVIRONMENTAL IMPACT; FUNGI; TEMPERATURE;

CONTINGENCY; DRUG RESISTANCE; ENVIRONMENTAL;

TRANSDUCERS;

CALCINEURIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CHAPERONE; CYCLOSPORIN A; FLUCONAZOLE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; CYCLOPEPTIDE; CYCLOPHILIN A; ERGOSTEROL; HSP82 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN;

BIOLOGY;

ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS TERREUS; CANDIDA ALBICANS; DRUG MECHANISM; ENVIRONMENTAL CHANGE; EVOLUTION; FEVER; FUNGUS; GENE MUTATION; GENETIC SELECTION; GENETIC VARIABILITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; AIDS RELATED COMPLEX; ASPERGILLOSIS; ASPERGILLUS; BIOSYNTHESIS; CANDIDIASIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; MUTATION; PHYSIOLOGY;

ASPERGILLUS TERREUS; CANDIDA ALBICANS; FUNGI; SACCHAROMYCES CEREVISIAE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CALCINEURIN; CANDIDA ALBICANS; CANDIDIASIS; CYCLOPHILIN A; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; EVOLUTION; FLUCONAZOLE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MUTATION; PEPTIDES, CYCLIC; PHENOTYPE; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SELECTION (GENETICS);

EID: 25844530060     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1118370     Document Type: Article

References (40)

1. J. C. Young, I. Moarefi, F. U. Hartl, J. Cell Biol. 154, 267 (2001).
2. D. Picard, Cell. Mol. Life Sci. 59, 1640 (2002).
3. W. B. Pratt, D. O. Toft, Exp. Biol. Med. 228, 111 (2003).
4. S. L. Rutherford, S. Lindquist, Nature 396, 336 (1998).
5. C. Queitsch, T. A. Sangster, S. Lindquist, Nature 417, 618 (2002).
6. V. Sollars et al., Nat. Genet. 33, 70 (2003).
7. S. F. Falsone, S. Leptihn, A. Osterauer, M. Haslbeck, J. Buchner, J. Mol. Biol. 344, 281 (2004).
8. Y. Xu, S. Lindquist, Proc. Natl. Acad. Sci. U.S.A. 90, 7074 (1993).
9. Y. Xu, M. A. Singer, S. Lindquist, Proc. Natl. Acad. Sci. U.S.A. 96, 109 (1999).
10. L. E. Cowen, J. B. Anderson, L. M. Kohn, Annu. Rev. Microbiol. 56, 139 (2002).
11. J. B. Anderson et al., Genetics 163, 1287 (2003).
12. D. Sanglard, Curr. Opin. Microbiol. 5, 379 (2002).
13. T. C. White, K. A. Marr, R. A. Bowden. Clin. Microbiol. Rev. 11, 382 (1998).
14. F. C. Odds, A. J. Brown, N. A. Gow. Trends Microbiol. 11, 272 (2003).
15. See supporting data on Science Online.
16. L. E. Cowen, S. Lindquist, unpublished data.
17. L. Whitesell, E. G. Mimnaugh, B. De Costa, C. E. Myers, L. M. Neckers, Proc. Natl. Acad. Sci. U.S.A. 91, 8324 (1994).
18. S. M. Roe et al., J. Med. Chem. 42, 260 (1999).
19. T. A. Sangster, S. Lindquist, C. Queitsch, Bioessays 26, 348 (2004).
20. J. B. Anderson, C. Sirjusingh, N. Ricker, Genetics 168, 1915 (2004).
21. M. C. Cruz et al., EMBO J. 21, 546 (2002).
22. D. Sanglard, F. Ischer, O. Marchetti, J. Entenza, J. Bille. Mol. Microbiol. 48, 959 (2003).
23. D. S. Fox, J. Heitman, Bioessays 24, 894 (2002).
24. J. Imai, I. Yahara, Mol. Cell. Biol. 20, 9262 (2000).
25. R. Kumar, A. Musiyenko, S. Barik, Mol. Biochem. Parasitol. 141, 29 (2005).
26. C. S. Hemenway, J. Heitman, Cell Biochem. Biophys. 30, 115 (1999).
27. D. S. Heckman et al., Science 293, 1129 (2001).
28. T. C. White, Antimicrob. Agents Chemother. 41, 1482 (1997).
29. M. A. Pfaller, D. J. Diekema, J. Clin. Microbiol. 42, 4419 (2004).
30. D. P. Kontoyiannis, R. E. Lewis, N. Osherov, N. D. Albert, G. S. May, J. Antimicrob. Chemother. 51, 313 (2003).
31. W. J. Steinbach et al., Antimicrob. Agents Chemother. 48, 1664 (2004).
32. L. E. Cowen, J. R. Köhler, S. Lindquist, unpublished data.
33. J. R. Blankenship, W. J. Steinbach, J. R. Perfect, J. Heitman, Curr. Opin. Investig. Drugs 4, 192 (2003).
34. R. Bagateli, L. Whitesell, Mol. Cancer Ther. 3, 1021 (2004).
35. A. Kamal, M. F. Boehm, F. J. Burrows, Trends Mol. Med. 10, 283 (2004).
36. J. D. Hasday, K. D. Fairchild, C. Shanholtz, Microbes Infect. 2, 1891 (2000).
37. H. L. True, I. Berlin, S. L. Lindquist, Nature 431, 184 (2004).
38. M. Kirschner, J. Gerhart, Proc. Natl. Acad. Sci. U.S.A. 95, 8420 (1998).
39. A. Bergman, M. L. Siegel, Nature 424, 549 (2003).
40. We thank O. Matangkasombut, G. R. Fink, J. B. Anderson, L. M. Kohn, and T. C. White for strains; K. Kuchler for an antibody to Pdr5; and Pfizer for fluconazole. Supported by a MIT Center for Environmental Health Sciences Pilot Project grant (National Institute of Environmental Health Sciences Center grant P30ES02109) and by the G. Harold and Leila Y. Mathers Charitable Foundation. L.E.C. is a Damon Runyon Fellow supported by Damon Runyon Cancer Research Foundation grant DRG-1765-03.